Baxter to Showcase New Data on Home Dialysis and HDx Therapy at 14 Clinical Presentations at Kidney Week 2022, Canadian Business Journal

garretschoenbergNovember 8, 2022

Controlled study conducted in 21 hospitals shows that remote patient management reduces adverse events in home peritoneal dialysis patients
A new ex vivo study serranova A dialyzer that effectively balances higher removal of large middle-molecule toxins and albumin stability during hemodialysis

DEERFIELD, Ill., Nov. 8, 2022 (GLOBE NEWSWIRE) — Baxter International Inc. (NYSE:BAX), a global innovator in renal care, presents 14 key insights into increasing access and the role innovation plays in increasing access. A new data presentation facilitated the scientific exchange. Learn about quality of home dialysis and extended hemodialysis (HDx) care at Kidney Week November 3-6, 2022 in Orlando, Florida. Key data highlighted are:

Study showing significant reduction in all-cause mortality and fluid balance, cardiovascular and metabolic adverse events in home automated peritoneal dialysis (APD) patients share source Remote Patient Management (RPM) Versus Non-RPM Patients with APD, “Adverse Events and Hospitalizations with Remote Patient Monitoring in Automated Peritoneal Dialysis Patients” [Abstract #FR-PO504].
A simulated dialysis study showing that extended hemodialysis (HDx) is possible serranova It presents the best balance when aiming to achieve higher clearance of higher molecular weight medium molecules while minimizing loss of albumin. [Abstract #SA-PO405].

MB BS’s Peter Rutherford said: Ph.D., Vice President, Medical Affairs, Baxter Renal Care. “Science exchanges are an important part of our collaboration and educational initiatives, and we are very pleased to support them at Kidney Week this year.”

Sharesource Remote Patient Management

Baxter’s share source The RPM Digital Health Platform allows healthcare providers to monitor a patient’s home dialysis treatment and remotely adjust treatment without the need for the patient to make an unscheduled visit to the clinic. share source currently uses Baxter’s APD cyclers to serve more than 50,000 patients in more than 70 countries. RPM research [Abstract #FR-PO504] Presented at Kidney Week 2022 is a cluster-randomized controlled trial conducted in 21 hospitals across Mexico that randomly assigned care units to treat APD patients with or without RPM .

HDx with Theranova

HDx enabled by serranova By targeting effective removal of large intermediate molecules (up to 45,000 Da), it removes a wider range of molecules from the blood than traditional HD filters such as high-flux membranes.¹^,²^,³ It selectively retains essential proteins and maintains stable albumin levels.^Four^,^Five^,⁶ These intermediate molecules are associated with the development of inflammation, cardiovascular disease, and other comorbidities in dialysis patients.⁷^,⁸

new serranova data [Abstract #SA-PO405] It comes from a simulated study that evaluated the challenges associated with increasing the removal of larger intermediate molecules while avoiding clinically relevant loss of albumin during dialysis sessions. During the study, four commercially available dialyzers with comparable surface areas were carefully evaluated for solute clearance and albumin loss during his 4-h simulated hemodialysis treatment under standardized conditions.

serranova Clearance of small and medium molecules was significantly higher (up to 2-3 fold for YKL40) and albumin loss was lower than the other two dialyzers. One dialyzer removed a large amount of large intermediate molecules, but the loss of albumin was more than twice his amount observed with the dialyzer. serranovaThis study indicates that further evaluation of dialyzer performance in clinical studies is needed to better understand the benefits of these findings.

HDx enabled by serranova Currently available in 54 countries across Europe, Latin America, Asia, Africa, and the United States and Canada. More than 9 million dialysis treatments are performed worldwide. serranova in over 850 clinics.U.S. Food and Drug Administration Approved serranova a de novo Established as a new class of dialyzer technology with unique performance criteria.

of serranova Dialyzer is indicated for patients with chronic renal failure who are prescribed intermittent hemodialysis. Increased clearance of various intermediate molecules (up to 45 kDa) that may play a pathological role in the uremic clinical syndrome provides an enhanced solute clearance profile.of serranova The dialyzer is not for hemofiltration or hemodiafiltration therapy.total extracorporeal blood volume of serranova The dialyzer and set should be less than 10% of the patient’s blood volume.

receive only: For the safe and proper use of the devices described here, please refer to the instructions for use.

About Baxter

Every day, millions of patients, caregivers, and health care providers use diagnostic, critical care, renal care, nutritional, hospital and surgical products used in patient homes, hospitals, clinics, and other health care settings. Depends on Baxter’s major portfolio. For more than 90 years, we have been at the critical intersection where life-saving and sustaining innovations meet the healthcare providers who make them happen. With products, digital health solutions, and therapies available in more than 100 countries, Baxter employees around the world are empowered by the company’s medical breakthroughs to drive the next generation of transformative healthcare innovation. Building a rich legacy. For more information, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

This release contains forward-looking statements regarding potential benefits associated with this release. share source When serranovaThese statements are based on assumptions regarding a number of important factors, including: These factors could cause actual results to differ materially from forward-looking statements. Product development risk; inability to generate additional production capacity in a timely manner or other manufacturing or supply problems (including consequences of natural disasters, public health crises, epidemics/pandemics, regulatory actions, etc.) ); satisfaction of regulatory and other requirements. Actions of regulatory bodies and other governmental authorities. Product quality, manufacturing or supply, or patient safety issues. Changes in Laws and Regulations. and other risks identified in Baxter’s most recent filings on Forms 10-K and 10-Q and other SEC filings. All of these are available on Baxter’s website. Baxter does not undertake to update any forward-looking statements.

Baxter, share source When serranova is a registered trademark of Baxter International Inc.

media contact
Jill Carey Hargrave, (224) 948-5353
[email protected]

investor contact
Claire Trachtman, (224) 948-3020

¹ Hutchison CA, Wolley M. Rationale for extended hemodialysis therapy.
² Hemodialysis performance with Kirsch AH, Lyko R, Nilsson LG, and others novel medium cut-off dialyzers.
³ Boschetti-de-Ferro MCO membrane.
^Four Kirsch AH, et al. Hemodialysis performance with a novel medium cut-off dialyzer. Nephrol Dial Transpl 2017; 32(1):165-72.
^Five Krishnasamy R et al. A Trial to Assess Membrane Clearance of Albumin and Light Chain Intermediate Cutoffs in Hemodialysis Patients (REMOVAL-HD): A Safety and Efficacy Study. ASN 2018 Kidney Week Abstract TH-PO353.
⁶ Long-term effects of extended hemodialysis (HDx) on clinical and laboratory parameters in a large cohort of Bunch A and other dialysis patients. ASN 2018 Kidney Week Abstract FR-PO766.
⁷ Ronco C and others Brad Prif. 2017;44(2):I-VIII.
⁸ Hutchison CA and others Contrib Nephrol. 2017; 191:142-152.